Phase I trial demonstrates AFM13-NK cells are safe and highly effective in heavily pretreated patients HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center. Results from the Phase I trial, published today in Nature Medicine, demonstrated an overall […]
